Angiotensin-converting enzyme inhibitors (ACEIs) are widely prescribed for several cardiovascular indications. This study investigated patterns of ACEI use for various indications.
Introduction
Angiotensin-converting enzyme inhibitors (ACEIs) are one of the most frequently prescribed classes of medication. For instance, in 2013, ramipril (an ACEI) was the first antihypertensive medication with more than 24 million prescriptions dispensed in community pharmacies in the UK [1] . ACEIs are commonly used to treat hypertension, heart failure (HF), myocardial infarction (MI) and renal disease (RD). It has been demonstrated that these drugs decrease cardiovascular disease morbidity and mortality, especially in patients with hypertension and HF [2] [3] [4] . Studies on the use of all antihypertensive medications have consistently shown that ACEIs have the second lowest risk of discontinuation [lowest are angiotensin II-receptor blockers (ARBs)] [5] [6] [7] [8] [9] . Nonetheless, a substantial number of patients discontinue ACEI therapy, mainly because of adverse drug reactions (ADRs) [10] . A US cohort study of >2200 outpatients who received ACEIs for the first time showed that 19% discontinued ACEIs due to ADRs (median follow-up 336 days) [11] . In a Dutch study on ACEI use based on a pharmacy drug-dispensing database, Vegter et al. reported that approximately 24% of ACEI starters switched their therapy within the first 3 years, and 75% of this group switched to ARBs [12] . In the UK, the percentage of ACEI switchers increased to >40% in a large population-based cohort of newly diagnosed hypertensive patients including a subgroup of more than 36 000 ACEI starters with a maximum of 9 years of follow-up [13] .
No study has investigated whether persistence with ACEIs differs among indications. A prior UK study showed that patients with MI were less likely to stop β-blocker therapy than patients with HF or angina pectoris [14] . The aim of this study is to investigate whether the pattern of ACEI use differs by indication for persistence rate, stop, restart or switch to ARBs.
Methods

Setting
The data for this study were obtained from the Clinical Practice Research Datalink (CPRD), formerly known as General Practice Research Database, which contains computerized information from almost 700 UK primary care practices. At the time of this study, CPRD included clinical records of close to 12 million patients. Validity data and a detailed description of the CPRD have been described previously [15, 16] .
The protocol for this study was reviewed and approved by the UK independent scientific advisory committee (ISAC), protocol number: 14_030R. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Study cohort
A descriptive, retrospective population-based study was conducted with patients aged 45 years and older who initiated ACEI therapy between 1 January 2007 and 1 January 2014. To be eligible for the study, patient data had to include at least 12 months of valid prescription history before starting an ACEI and at least 6 months of valid prescription data after starting, so ACEI persistence could be evaluated. Assessment of validity was performed using general practitioner prescription data for any medication prescribed for the study participants.
Follow-up
Subjects were followed through the study period, time of death or the date they moved outside the practice area. Subject mortality data are available through an established link between CPRD and the UK office for national statistics. The cohort entry date was the date of the patient's first ACEI prescription. To categorize patients according to the indication for ACEI initiation, we assessed whether they had a diagnosis (based on relevant Read codes in electronic medical records) of hypertension, HF, MI or RD prior to the cohort entry date or in the first year thereafter. Patients with more than one indication and patients for whom we could not retrieve any of the above indications within that period were classified in separate categories. The category of more than one indication was further subdivided based on the number and combination of indications (Supplementary Table S1 ). Both the average follow-up time and duration of ACEI use were calculated for each indication.
1 Persistent group: Patients who started ACEIs and continued until the end of follow-up. A maximum 6-month time interval between two prescription periods was acceptable for this definition. This time interval has been shown to be a better indicator of ADRs in comparison to a 3-month interval [10] . Even if a patient is hospitalized (usually no longer than 1 month) or has a stock of the medication, they are expected to return for a refill of their prescription within this period. 2 Nonpersistent group: Patients who stopped receiving ACEI prescriptions for at least 6 months after the theoretical end date of their previous ACEI prescription. The discontinuation date was defined as the theoretical end date of the last ACEI prescription and calculated by dividing the quantity of prescribed medications by the number of daily doses. The nonpersistent group was further divided into three mutually exclusive subgroups according to the treatment pattern after ACEI discontinuation ( Figure 1 ). 
Statistical analyses
General characteristics for all ACEI starters were reported separately for each indication (hypertension, HF, MI, RD, more than one indication and none of the above). Five-year persistence rates and the time to discontinuation among the various indications were calculated and compared using the Kaplan-Meier method and a log-rank test, respectively. Patients who started with an ACEI and had a follow-up time of <6 months were excluded, since these patients would have automatically been placed in the persistent group due to the definition of persistence. This result could have unrealistically increased the estimation of the proportion of persistent patients. To evaluate the influence of these exclusions, we performed a sensitivity analysis in which excluded patients were analysed once as persistent ACEI users and once as nonpersistent users. All statistical analyses were performed using SPSS 20 (IBM SPSS Statistics for Windows Version 20.0. Armonk, NY: IBM Corp).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [17] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [18, 19] .
Results
There were 276 973 eligible patients who had started with an ACEI during the study period. A total of 22 971 patients (8.2%) were excluded from the main analyses due to a <6-month follow-up time. Table 1 presents the general characteristics of the remaining 254 002 patients (51.5% male) at the first date of ACEI prescription. Table 1 also includes the average follow-up time, average duration of ACE inhibitor use and proportions of deceased patients during follow-up; all were stratified by indication. The majority of participants Figure 1 Definition of angiotensin-converting enzyme inhibitor (ACEI) use patterns. ARB, angiotensin II-receptor blocker Prescription patterns of ACE inhibitors for various indications had started with an ACEI because of hypertension (57.6%) and the smallest group for HF (1.5%). The patient group with more than one indication represented 17.2% of the sample, and 90.1% of these participants had hypertension as one indication. Patients who started an ACEI for HF and RD were approximately 9 years older than patients with an MI or hypertension.
The highest percentages of death were for patients with HF (21.5%) or more than one indication (15.4%). The mean duration of ACEI use was longest for those who had had an MI (30.5 months) and shortest for those with HF (25.0 months) or RD (23.6 months; Table 1) . Table 2 shows the patterns of ACEI use by indication. In the total study population, 60.3% of ACEI starters continued till the end of study follow-up. For the 100 790 nonpersistent patients, 45.3% stopped their ACEI (did not switch to ARBs within 6 months and never restarted ACEIs), 37.1% switched to ARBs and 17.6% restarted their ACEIs after at least 6 months of discontinuation.
Patients who started an ACEI for MI had the highest probability of remaining on their initial ACEI treatment (73.6%). Patients who started an ACEI for RD were most likely to discontinue (49.2%). More than half (54.5%) of the nonpersistent patients with RD actually stopped and did not restart ACEIs or switch to ARBs. This was the highest percentage for this behaviour among all indications.
Study participants who switched from ACEIs to ARBs ranged from 27.6% (RD) to 42.2% (MI). Out of 24 206 patients with hypertension, who stopped their ACEI and did not restart or switch to ARBs, 17.2% switched to calcium channel blockers, which was the highest percentage, followed by a switch to diuretics (6.3%), a combination of antihypertensives (5.0%) or β-blockers (3.6%). The same pattern was observed for patients with hypertension combined with other indications (10.0% switched to calcium channel blockers, 6.3% to diuretics, 3.3% to a combination of antihypertensives and 3.2% to β-blockers).
Kaplan-Meier curves of ACEI use for various indications are presented in Figure 2 . Five-year persistence rates for indications included in this study were 68.2% (MI), 58.6% (HF), 56.4% (hypertension), 53.4% (no mentioned indication), 53.0% (more than one indication) and 43.2% (RD; log-rank P < 0.0001).
Sensitivity analyses, including the 22 971 patients with <6 months of follow-up, changed the crude percentages for the nonpersistent patients for all indications. For example, in the MI group, the percentage of nonpersistent patients changed from 26.4% to 34.4% (excluded patients were included as nonpersistent patients) and to 23.6% (excluded patients were included as persistent patients). Detailed results of sensitivity analyses are presented in Supplementary Table S2 .
Discussion
This study demonstrated that patterns of ACEI use and persistence differ among indications. Patients with RD discontinued their ACEI therapy more frequently and used ACEIs for a shorter time period than those with other Table 1 General characteristics of included patients stratified by indications (n = 254 002 patients) Minimum requirement of a 6-month follow-up after angiotensin-converting enzyme inhibitor initiation SD: standard deviation, SDM: standardized difference between means as compared to the hypertension group as the most common indication indications. Five-year nonpersistence rates ranged between 31.8% (MI) and 56.8% (RD). Hypertension, RD and HF are three main indications of ACEIs previously studied for drug utilization patterns. Although ACEIs are well tolerated compared to other antihypertensive medications, the problem of poor persistence still exists for patients with hypertension. For example, a 1-year discontinuation rate for lisinopril (ACEI) consumers in the USA and Australia with hypertension was reported to be >30% [20, 21] .
Several sociodemographic factors have been shown to be associated with nonpersistence to antihypertensive therapy (e.g. sex, comedications, comorbidities and even demographic characteristics of patient geographic location) [22, 23] , which can eventually result in poor clinical outcomes [24] . A Dutch study showed that the putative ACEI-related cough can affect patient compliance (20% higher compliance for patients without a putative cough);
however, the precise cause of ACEI discontinuation could not be retrieved directly [25] . In the early 2000s, two studies using the same population (Régie de l'assurance maladie du Québec administrative database) showed that among patients with hypertension (and specifically ACEI users), those patients who had many risk factors for cardiovascular events were more persistent with their drug therapy than patients with fewer risk factors [26, 27] . Patients who start ACEIs for RD are more susceptible to adverse effects such as renal function deterioration or hyperkalaemia (in addition to the common side effect of coughing) because of a combination of drug action and disease complications. Therefore, it is not uncommon to recommend that patients with RD discontinue (permanently or temporarily) their ACEIs [28] . It has also been shown that older age in patients with hypertension is associated with a higher risk of nonpersistence to ACEIs [29] . In our study, the mean age of patients with RD was higher than patients with a Switched to calcium channel blockers (17.2%), diuretics (6.3%), combination of antihypertensives (5.0%), β-blockers (3.6%) and other antihypertensives (0.1%). b Two subgroups: a) more than one indication including hypertension (90.5%) and b) not including hypertension (9.5%). Group A percent switched to calcium channel blockers (10.0%), diuretics (6.3%), combination of antihypertensives (3.3%), β-blockers (3.2%) and other antihypertensives (0.3%). ARB, angiotensin II-receptor blocker other conditions, which could potentially have influenced the higher nonpersistence rate in this group. ACEIs are one of the main medications used in HF management and large population-based studies have demonstrated that drug adherence is significantly associated with increased survival time in these patients [30] . Recently, it has been shown in the USA that medication adherence for patients with HF decreases during the first few months after hospitalization [31] . A 2015 French study showed that the pharmacological management of HF in elderly patients is not optimal [32] ; however, a 2015 systematic review of 17 studies (162 727 patients) found that older age alone is not related to the poor medical management in patients with HF [33] . In our study, patients with HF were the third oldest group and had the highest mortality rate. This might explain the average time-limited use of ACEI in this group.
Our study demonstrates that patients who start ACEIs for RD and HF have a higher probability of stopping and should have improved follow-up and monitoring by health care providers to achieve the full benefit of ACEIs. We suggest either pharmacists or physicians contact patients who have discontinued relevant medication (specifically ACEIs) without clear justification, to improve persistence and thus, patient outcomes [34, 35] .
More studies are needed to address the issue of whether or not ACEI discontinuation is inevitable or can be managed by a dose adjustment, addition of a new class of medication or other interventions.
The main strength of this population-based study was the large number of patients who can be considered as representative of all ACEI starters in the UK. Valid data for at least 18 months (12 months before and 6 months after the first ACEI prescription) was an acceptable follow-up time to identify new users and define usage and persistence patterns.
One of the limitations of this study was that the indications for ACEI use were based on electronic medical records registered by general practitioners. These diagnoses were not validated, so misclassifications cannot be ruled out. That said, a recent study compared CPRD codes for renal replacement therapy and decreased kidney function with external data sources in the UK (Health Survey for England and UK Renal Registry). The authors found an acceptable validity when comparing the prevalence of the abovementioned kidney diseases in the CPRD with external data sources [36] . Another recent study could not find significant prognostic differences between patients with HF who were recorded in CPRD primary care data alone and those who were recorded both in hospital admission and primary care data [37] . Unequal follow-up time for all patients could potentially be another limitation. However, we tried to decrease the variation between patient follow-up times by excluding patients with very short follow-up times (<6 months of follow-up after ACEI initiation).
In conclusion, this UK study demonstrated that for all patients with various indications for ACEIs a relatively high percentage will stop or switch their therapy, and the highest proportion of stoppers are patients with RD. The main cause of nonpersistence to ACEIs within these patient groups needs to be further investigated.
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